References
Treating masseteric hypertrophy with botulinum toxin
Abstract
Introducing MSFIT – a modified technique for improving safety in masseter botulinum toxin injections
Benign masseter muscle hypertrophy can clinically present as an enlargement of the muscle near the angle of the mandible. Associated pain, functional impairment or aesthetic changes can be treated surgically or non-surgically. The choice of treatment depends on the underlying aetiology, of which there can be multiple. Botulinum toxin type A (BoTNA), the least invasive modality, is commonly used. Treatment selection depends on underlying causes, patient goals (functional, aesthetic, or both), risks and downtime.
The masseter, the most prominent masticatory muscle, primarily functions to elevate the mandible against the maxilla, generating masticatory forces (Mezey et al, 2021). Beyond its crucial role in dental function, it significantly contributes to the aesthetic appearance of the lower face. Botulinum toxin type A (BoTNA) was first utilised in 1994 to address masseteric muscle hypertrophy (MMH) by inducing muscle atrophy through partial paralysis, and since then has become an effective non-surgical technique in reshaping the lower face, addressing both functional and aesthetic concerns (Kundu et al, 2022). Recognised as the standard treatment for MMH, BoTNA offers a safe, convenient solution with minimal downtime, albeit requiring multiple treatments for sustained results (Kundu et al, 2022). Studies demonstrate a high satisfaction rate of 84% attributed to effective volume reduction of the masseter, minimal complications, and the ease of the procedure (Galadari et al, 2021).
Register now to continue reading
Thank you for visiting Journal of Aesthetic Nurses and reading some of our peer-reviewed resources for aesthetic nurses. To read more, please register today. You’ll enjoy the following great benefits:
What's included
-
Limited access to clinical or professional articles
-
New content and clinical newsletter updates each month